ClinicalTrials.gg
RecruitingNCT06935084Updated Sep 8, 2026

ASTHMAXcel Voice Study

An interventional study of ASTHMAXcel Voice platform in Asthma, sponsored by Montefiore Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Montefiore Medical Center · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Asthma by Montefiore Medical Center — 3 open to participants now, 3 under way, none of them phase 3. Asthma · Montefiore Medical Center.

Planned enrollment
6th of 16
200 · median 171
Started
2025
the only one that year
No phase
14 of 17
2 open now
Registered
15th of 17
by date

Among the 17 studies in Asthma by Montefiore Medical Center, this one is the 6th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2025, is one of 14 with no phase, and was the 15th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 17 studies in Asthma by Montefiore Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Asthma by Montefiore Medical Center, or all of them as a file.
02

Study summary

The objective of this study is to conduct a randomized controlled trial (RCT) to compare the adapted and refined ASTHMAXcel Voice platform to usual care (UC). It is hypothesized by the investigator team that ASTHMAXcel Voice will be associated with improved clinical and process outcomes, asthma quality of life (QOL), medication adherence, and self-efficacy as compared to UC.

Read the detailed description

Poor outcomes for minority patients with asthma have been linked to poverty and other social determinants of health (SDOH), environmental exposures, and poor self-management. In a previous Agency for Healthcare Research and Quality (AHRQ)-funded study, the researchers developed and pilot tested ASTHMAXcel PRO, a mobile app that promotes self-management of asthma (NCT03847142). The app was optimized for outpatient settings and promoted asthma self-management through the collection of patient-reported outcomes (PROs), animated videos, goal setting, personalized algorithms, and push notifications. The use of the app led to significant decreases in the need for steroids, visits for asthma to the emergency department, and hospitalizations for asthma.

In this current research, ASTHMAXcel Voice, an app developed and refined during enhancement of ASTHMAXcel PRO, will make use of voice biomarkers to detect worsening symptoms. This technology uses machine learning to assess respiratory dysfunction, including asthma, based on a 6-second voice sample. From the sample, a Respiratory Symptoms Risk Score (RSRS) is calculated that correlates with the speaker's risk of respiratory impairment. The updated platform will calculate the patient's RSRS; facilitate shared decision making, screen for SDoH, and referrals; improve the ability of patients to self-manage; and allow for remote care coordination.

This program draws upon the Common Sense Model (CSM) of Self-Regulation which describes a cognitive processing system that includes situational stimuli (asthma symptoms), objective representation of the health threat (illness representations) with its treatment decision (controller medication use), and appraisal of outcomes (asthma control) for the success/failure of those treatment decisions. The model contains a feedback loop with illness representations changing over time as patients gain experience with asthma management. Social Determinants of Health (SDoH) may also affect the representation of the health threat, treatment decisions, and appraisal of outcomes. As an example, a patient with depression, a poor social support network, insecure housing, and financial stress may view asthma as an acute disease that is uncontrollable, which in turn leads to negative beliefs about medications and low self-efficacy towards asthma management. ASTHMAXcel Voice strives to shift illness representations away from the belief that asthma only exists when there are active symptoms and change behavior towards daily controller medication use over the long term to prevent asthma symptoms. Realtime feedback based on voice samples that yield a RSRS (voice biomarker) will help the patient to accurately detect perceived threats and manage asthma exacerbations during earlier stages. ASTHMAXcel Voice is also based on the SEM that addresses causes of poor asthma control across four interconnected domains: community, medical system, interpersonal, and individual level factors. ASTHMAXcel Voice is a multilevel approach to address these barriers with intervention components that are directly applied at each level.

There is growing recognition that mobile health interventions can be applied across all these levels to facilitate health behavior change through the use of push notifications and interactive educational content. ASTHMAXcel Voice works on the individual and interpersonal levels by providing targeted asthma education and push notifications to assist with medication adherence and asthma management. Worse outcomes assessed by PROs (asthma control) and voice biomarkers may heighten the perceived threat level of asthma and prompt Just-in-Time Adaptive Interventions (JITAIs) to seek out the educational content more frequently to improve asthma control. On the organizational (medical system) level, ASTHMAXcel Voice will facilitate shared decision-making and ongoing communication between the patient, Community Health Worker (CHW) or Social Worker (SW), and Health Care Provider (HCP). For example, a monthly visual dashboard display will increase HCP awareness of deteriorating trends assessed from PROs and voice biomarkers. On the community level, the CHW or SW will provide patients with SDoH relevant community resources (e.g., pest remediation services, smoking cessation programs, support groups, food pantries) to address SDoH concerns reported in the mobile platform. Finally, to inform more effective design and implementation of ASTHMAXcel Voice, the study team will use the Unified Theory of Acceptance and use of Technology (UTAUT) health IT framework in determining a user's technology acceptance and adoption behavior.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Mobile Health Application
  • Asthma Management
  • Asthma Control
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English speaking
  • Persistent asthma (diagnosed by a healthcare provider) on a daily controller medication
  • Able to provide
  • Smartphone access (iOS or Android) with data plan

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Severe psychiatric or cognitive problems that would prohibit completion of protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    ASTHMAXcel

    Participants in this arm will be provided with the adapted and refined ASTHMAXcel Voice platform.

    Other: ASTHMAXcel Voice platform

  • No intervention
    Usual Care (UC)

    Participants in this arm will receive standard care.

Interventions

  • OtherASTHMAXcel Voice platform

    ASTHMAXcel Voice is a mobile health application with a multi-level approach to address barriers with intervention components and facilitate health behavior change through the use of push notifications and interactive educational content.

06

What researchers measure

Primary outcomes

  1. Change in Asthma Control

    Change in asthma control will be assessed and measured using the Asthma Control Test (ACT). The ACT is a 5-item questionnaire administered to assess asthma control. Participants will score each item on the ACT based on a 5-point Likert scale ranging from 1 (poor control) to 5 (excellent control) yielding an overall possible scoring range of 5-25, such that higher overall scores are associated with increased levels of asthma control. Change in ACT scores will be summarized by study arm using basic descriptive statistics. Paired t-tests will also be used to compare ACT scores between baseline and 2 months and baseline and 6 months within each arm.

    Time frame: Change from Baseline to 6 months after randomization

Secondary outcomes

  1. Change in Asthma Control

    Change in asthma control will be assessed and measured using the Asthma Control Test (ACT). The ACT is a 5-item questionnaire administered to assess asthma control. Participants will score each item on the ACT based on a 5-point Likert scale ranging from 1 (poor control) to 5 (excellent control) yielding an overall possible scoring range of 5-25, such that higher overall scores are associated with increased levels of asthma control. Change in ACT scores will be summarized by study arm using basic descriptive statistics. Paired t-tests will also be used to compare ACT scores between baseline and 2 months and baseline and 6 months within each arm.

    Time frame: Change from Baseline to 2 months after randomization

  2. Change in User Acceptance of ASTHMAXcel Voice Application

    Change in user acceptance of the application will be assessed using the Unified Theory of Acceptance and User of Technology (UTAUT) Questionnaire. The UTAUT considers 4 constructs: performance expectancy (PE), effort expectancy (EE), social influence (SI), and facilitating conditions (FC), as most influential in determining technology acceptance and adoption behavior. Each of the 4 constructs consists of 4 statements which are evaluated on a 5-point Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly Agree), with higher scores indicating a greater likelihood of technology acceptance and use, reflecting stronger perceptions of PE, EE, SI, and FC. Scores for all items are summed and then the total score is divided by 16 to calculate a mean or average score. Scores will be summarized by using basic descriptive statistics. Paired t-tests will also be used to assess changes in user acceptance between baseline and 2 months and baseline and 6 months within the arm.

    Time frame: Baseline, 2 months, and 6 months after randomization

  3. Change in User Satisfaction of Interaction with the ASTHMAXcel Voice application

    Change in User satisfaction of Interaction with the application will be assessed using Version 7 of the Questionnaire for User Interface Satisfaction (QUIS). The QUIS is a measurement tool designed to assess a computer user's subjective satisfaction with specific aspects of the human-computer interface. QUIS measures specific interface factors such as screen visibility, terminology and system information, learning factors, system capabilities, usability and user interface, and system clutter, across 32 questions. Each QUIS question is measured on an ascending scale ranging from 0-9, wherein higher scores are associated with more favorable user impression of aspects of the interface. Scores for all items are summed and divided by the number of items answered to calculate a mean or average score. Scores will be summarized by using basic descriptive statistics. Paired t-tests will also be used to assess changes between baseline and 2 months and baseline and 6 months within the arm.

    Time frame: Baseline, 2 months, and 6 months after randomization

  4. ASTHMAXcel Voice application Usage

    ASTHMAXcel Voice application usage will be evaluated using analytics within the "Admin Panel" of the application. Specifically, the number of logins to ASTHMAXcel Voice will be determined and considered as a proxy for usage. Usage will be summarized using basic descriptive statistics.

    Time frame: 2 months and 6 months after randomization

  5. Change in Overall User Satisfaction

    Overall User Satisfaction will be assessed using the 8-item Client Satisfaction Questionnaire (CSQ-8). The CSQ-8 is a brief global measure of client satisfaction which contains four response choices (1-4), where "1" indicates the lowest degree of satisfaction and "4," the highest. Scores are summed across each item once. Responses to items 2, 4, 5, and 8 are reverse scored. Total overall scores range from 8-32, where in higher scores are indicative of greater overall user satisfaction. Scores will be summarized by using basic descriptive statistics. Paired t-tests will also be used to assess changes between post-refinement baseline and 2 months and baseline and 6 months within the arm.

    Time frame: Baseline, 2 months, and 6 months after randomization

  6. Change in Shared Decision Making

    Patient-reported degree of shared decision making will be assessed using the 9-item Shared Decision-Making Questionnaire (SDM-Q-9). The SDM-Q-9 consists of 9 statements which asks the patient to assess the extent to which they agree or disagree with elements and perceptions of shared decision-making during clinical encounters. Each statement on the SDM-Q-9 is scored on a 6-point Likert scale ranging from 0 (completely disagree) to 5 (completely agree). Scores are summed to yield an overall possible scoring range of 0-45, with higher values being indicative of greater perceived shared decision making. Scores will be summarized by study arm using basic descriptive statistics. Paired t-tests will also be used to assess changes between post-refinement baseline and 2 months and 6 months within the arm

    Time frame: Baseline to 2 months and 6 months after randomization

  7. Change in Asthma-related Quality of Life

    Change in Asthma-related Quality of Life will be assessed using the Mini Asthma Quality of Life Questionnaire (MiniAQLQ). The MiniAQLQ is a 15-item questionnaire that assesses asthma-related quality of life. Participants are asked to evaluate each of the questions/statements to describe how much (relative) time has been spent attending to symptoms of asthma or how much asthma has limited activities over the past 2 weeks. Each of the 15 items is scored on a 7-point Likert scale ranging from 1 (severe impairment) to 7 (no impairment), such that higher scores are associated with a better overall quality of life. Scores for the 15-items are summed and divided by 15 to express as a score out of 7 (mean or average score). Change in asthma quality of life scores will be summarized by study arm using basic descriptive statistics. Paired t-tests will also be used to assess changes in asthma-related quality of life between baseline and 2 months and baseline and 6 months within each arm.

    Time frame: Baseline to 2 months and 6 months after randomization

  8. Asthma Healthcare Utilization - Emergency Department (ED) Visits

    The number of asthma-related ED visits at 2 months and 6-months post-randomization will be summarized by study arm using basic descriptive statistics.

    Time frame: 2 months and 6 months after randomization

  9. Asthma Healthcare Utilization - Hospitalizations

    The number of asthma-related hospitalizations at 2 months and 6-months post-randomization will be summarized by study arm using basic descriptive statistics.

    Time frame: 2 months and 6 months after randomization

  10. Change in Self-efficacy for managing chronic diseases

    Self-efficacy for managing chronic diseases will be evaluated using the Self-Efficacy for Managing Chronic Disease 6-Item (SEMCD-6) Scale. The SEMCD-6 assesses the level of confidence in managing six areas related to chronic disease: fatigue, physical discomfort/pain, emotional distress, other symptoms/health problems, tasks/activities needed to manage health conditions, and things other than just taking medication. Each question is rated on a 10-point scale ranging from 1 (not confident at all) to 10 (totally confident). Scores for all six items are summed, and then the total score is divided by six to calculate a mean or average score. Higher scores are associated with greater self-efficacy. Group scores will be summarized by study arm using basic descriptive statistics. Paired t-tests will also be used to assess changes between post-refinement baseline and 2 months and 6 months within the arm.

    Time frame: Baseline to 2 months and 6 months after randomization

  11. Change in Self-reported Medication Adherence

    Medication Adherence will be evaluated using the 5-Item Medication Adherence Report Scale (MARS-5). The MARS-5 is a self-reported tool used to assess medication adherence and consists of 5 questions including items related to forgetting, changing dosage, stopping, skipping, and taking less medication. Each question is answered on a 5-point Likert scale (1=always, 2=often, 3=sometimes, 4=rarely, and 5=never), resulting in an overall possible score of 5-25, with higher scores indicating a higher level of adherence. Group scores will be summarized by study arm using basic descriptive statistics. Paired t-tests will also be used to assess changes between post-refinement baseline and 2 months and 6 months within the arm

    Time frame: Baseline to 2 months and 6 months after randomization

  12. SDoH Screening

    SDoH Screening will be determined by the number of SDoH positive screens over the prior month. Group scores will be summarized by study arm using basic descriptive statistics.

    Time frame: 2 months and 6 months after randomization

  13. SDoH Referral

    SDoH Referral will be determined by the number of completed SDoH referrals over the prior month. Group scores will be summarized by study arm using basic descriptive statistics.

    Time frame: 2 months and 6 months after randomization

  14. Referral Completion Rate

    SDoH Referral Completion Rate will be assessed by the number of SDoH referral completions over the prior month. Group scores will be summarized by study arm using basic descriptive statistics.

    Time frame: 2 months and 6 months after randomization

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004 Jan;113(1):59-65. doi: 10.1016/j.jaci.2003.09.008. PubMed 14713908 ↗
  • Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: development of a general scale. Eval Program Plann. 1979;2(3):197-207. doi: 10.1016/0149-7189(79)90094-6. No abstract available. PubMed 10245370 ↗
  • Kriston L, Scholl I, Holzel L, Simon D, Loh A, Harter M. The 9-item Shared Decision Making Questionnaire (SDM-Q-9). Development and psychometric properties in a primary care sample. Patient Educ Couns. 2010 Jul;80(1):94-9. doi: 10.1016/j.pec.2009.09.034. Epub 2009 Oct 30. PubMed 19879711 ↗
  • Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J. 1999 Jul;14(1):32-8. doi: 10.1034/j.1399-3003.1999.14a08.x. PubMed 10489826 ↗
  • Chan AHY, Horne R, Hankins M, Chisari C. The Medication Adherence Report Scale: A measurement tool for eliciting patients' reports of nonadherence. Br J Clin Pharmacol. 2020 Jul;86(7):1281-1288. doi: 10.1111/bcp.14193. Epub 2020 May 18. PubMed 31823381 ↗
  • Ritter PL, Lorig K. The English and Spanish Self-Efficacy to Manage Chronic Disease Scale measures were validated using multiple studies. J Clin Epidemiol. 2014 Nov;67(11):1265-73. doi: 10.1016/j.jclinepi.2014.06.009. Epub 2014 Aug 3. PubMed 25091546 ↗
  • Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999 Sep;89(9):1322-7. doi: 10.2105/ajph.89.9.1322. PubMed 10474547 ↗
  • Leventhal H, Brissette, I., Leventhal, E. A. The common sense model of self-regulation of health and illness. In: Cameron LD, Leventhal, H., ed. The self-regulation of health and illness behavior. London, UK: Taylor and Francis Books; 2003:42-65.
  • Sofianou A, Martynenko M, Wolf MS, Wisnivesky JP, Krauskopf K, Wilson EA, Goel MS, Leventhal H, Halm EA, Federman AD. Asthma beliefs are associated with medication adherence in older asthmatics. J Gen Intern Med. 2013 Jan;28(1):67-73. doi: 10.1007/s11606-012-2160-z. Epub 2012 Aug 10. PubMed 22878848 ↗
  • Arcoleo KJ, McGovern C, Kaur K, Halterman JS, Mammen J, Crean H, Rastogi D, Feldman JM. Longitudinal Patterns of Mexican and Puerto Rican Children's Asthma Controller Medication Adherence and Acute Healthcare Use. Ann Am Thorac Soc. 2019 Jun;16(6):715-723. doi: 10.1513/AnnalsATS.201807-462OC. PubMed 30860858 ↗
  • U B. Toward an experimental ecology of human development. American Psychologist. 1977;32(7):513 531.
  • Kolff CA, Scott VP, Stockwell MS. The use of technology to promote vaccination: A social ecological model based framework. Hum Vaccin Immunother. 2018 Jul 3;14(7):1636-1646. doi: 10.1080/21645515.2018.1477458. Epub 2018 Jul 3. PubMed 29781750 ↗
  • Venkatesh V MM, Davis GB, Davis FD. User acceptance of information technology: Toward a unified view. MIS quarterly. 2003;1:425-478.
  • U.S. Department of Health and Human Services NIoH. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (EPR-3). 2007 Jul.
  • Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol. 2009 Oct;124(4):719-23.e1. doi: 10.1016/j.jaci.2009.06.053. Epub 2009 Sep 19. PubMed 19767070 ↗
  • Hsia BC, Wu S, Mowrey WB, Jariwala SP. Evaluating the ASTHMAXcel Mobile Application Regarding Asthma Knowledge and Clinical Outcomes. Respir Care. 2020 Aug;65(8):1112-1119. doi: 10.4187/respcare.07550. Epub 2020 Jun 2. PubMed 32487751 ↗
  • Hanson JL, Balmer DF, Giardino AP. Qualitative research methods for medical educators. Acad Pediatr. 2011 Sep-Oct;11(5):375-86. doi: 10.1016/j.acap.2011.05.001. Epub 2011 Jul 23. PubMed 21783450 ↗
  • Hsia B, Mowrey W, Keskin T, Wu S, Aita R, Kwak L, Ferastraoarou D, Rosenstreich D, Jariwala SP. Developing and pilot testing ASTHMAXcel, a mobile app for adults with asthma. J Asthma. 2021 Jun;58(6):834-847. doi: 10.1080/02770903.2020.1728770. Epub 2020 Feb 19. PubMed 32046564 ↗
  • Figueroa JF, Frakt AB, Jha AK. Addressing Social Determinants of Health: Time for a Polysocial Risk Score. JAMA. 2020 Apr 28;323(16):1553-1554. doi: 10.1001/jama.2020.2436. No abstract available. PubMed 32242887 ↗

Individual participant data

Plan to share: Yes — Once primary study findings have been published, deidentified data publicly available along with its associated documentation. Public Use Data: All de-identified study data that are not designed as restricted use will be made publicly available as supplementary material of articles in PubMed Central. All datasets will require detailed metadata documentation (Word documents), including (but not limited to) the methodology and procedures used to collect the data, details about codes (codebooks), definitions of variables, variable field locations, frequencies, etc. All data sets that are shared will be accompanied by the relevant metadata. No other specialized tools will be needed to access or manipulate shared scientific data to support replication or reuse. Participant-level data from this study will be fully de-identified and represented as an OMOP-CDM v5.3.1 dataset (mapped to OHDSI/Athena vocabulary system)

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Results generated from this grant will be presented at national or international scientific meetings and conferences and will be published in a timely fashion. Data sets and associated documents will be provided to the NIH study Program Official within timelines described in the NIH Policy for Data Sharing from Observational Epidemiology Studies - no later than 3 years after the completion of each examination or follow-up cycle or 2 years after the baseline, follow-up, genetic, ancillary study, or other data set is finalized within the study for analysis for use in publication, whichever comes first. Study data will be made available to other users after publication of the study's main results have been published (estimated to be within 12 months of study closure). Once available, no time limit will be placed on accessibility of the study data.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2028, 36 months after the start.

Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 36 months is above that.

Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2025
First posted
Apr 18, 2025
StartActual
Sep 18, 2025
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06935084
Collaborators
Yeshiva University, Agency for Healthcare Research and Quality (AHRQ)
Responsible party
Sponsor
First posted
Apr 18, 2025
Start date
Sep 18, 2025
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Sep 8, 2026

Study contacts

Sunit Jariwala, MD
Contact
sjariwal@montefiore.org
609-937-1023
Juliana D Rodriguez, MD
Contact
juliana.rodríguez@einsteinmed.edu
718-862-1722
Sunit Jariwala, MD
principal investigator · Montefiore Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion